279 related articles for article (PubMed ID: 32434847)
41. Role of human Pegivirus infections in whole Plasmodium falciparum sporozoite vaccination and controlled human malaria infection in African volunteers.
Tumbo AM; Schindler T; Dangy JP; Orlova-Fink N; Bieri JR; Mpina M; Milando FA; Juma O; Hamad A; Nyakarungu E; Chemba M; Mtoro A; Ramadhan K; Olotu A; Makweba D; Mgaya S; Stuart K; Perreau M; Stapleton JT; Jongo S; Hoffman SL; Tanner M; Abdulla S; Daubenberger C
Virol J; 2021 Jan; 18(1):28. PubMed ID: 33499880
[TBL] [Abstract][Full Text] [Related]
42. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine.
Seder RA; Chang LJ; Enama ME; Zephir KL; Sarwar UN; Gordon IJ; Holman LA; James ER; Billingsley PF; Gunasekera A; Richman A; Chakravarty S; Manoj A; Velmurugan S; Li M; Ruben AJ; Li T; Eappen AG; Stafford RE; Plummer SH; Hendel CS; Novik L; Costner PJ; Mendoza FH; Saunders JG; Nason MC; Richardson JH; Murphy J; Davidson SA; Richie TL; Sedegah M; Sutamihardja A; Fahle GA; Lyke KE; Laurens MB; Roederer M; Tewari K; Epstein JE; Sim BK; Ledgerwood JE; Graham BS; Hoffman SL;
Science; 2013 Sep; 341(6152):1359-65. PubMed ID: 23929949
[TBL] [Abstract][Full Text] [Related]
43. A PfSPZ vaccine immunization regimen equally protective against homologous and heterologous controlled human malaria infection.
Mordmüller B; Sulyok Z; Sulyok M; Molnar Z; Lalremruata A; Calle CL; Bayon PG; Esen M; Gmeiner M; Held J; Heimann HL; Woldearegai TG; Ibáñez J; Flügge J; Fendel R; Kreidenweiss A; Kc N; Murshedkar T; Chakravarty S; Riyahi P; Billingsley PF; Church LWP; Richie TL; Sim BKL; Hoffman SL; Kremsner PG
NPJ Vaccines; 2022 Aug; 7(1):100. PubMed ID: 35999221
[TBL] [Abstract][Full Text] [Related]
44. Machine learning prediction of malaria vaccine efficacy based on antibody profiles.
Wistuba-Hamprecht J; Reuter B; Fendel R; Hoffman SL; Campo JJ; Felgner PL; Kremsner PG; Mordmüller B; Pfeifer N
PLoS Comput Biol; 2024 Jun; 20(6):e1012131. PubMed ID: 38848436
[TBL] [Abstract][Full Text] [Related]
45. Multi-Dose Priming Regimens of PfSPZ Vaccine: Safety and Efficacy against Controlled Human Malaria Infection in Equatoguinean Adults.
Jongo SA; Church LWP; Nchama VUNN; Hamad A; Chuquiyauri R; Kassim KR; Athuman T; Deal A; Natasha KC; Mtoro A; Mpina M; Nyakarungu E; Bidjimi GO; Owono MA; Mayé ERM; Mangue MEO; Okomo GNN; Pasialo BEN; Mandumbi DMO; Mikue MAL; Mochomuemue FL; Obono MO; Besahá JCM; Bijeri JR; Abegue GM; Veri YR; Bela IT; Chochi FC; Lima Sánchez JE; Pencelli V; Gayozo G; Nlang JAEM; Schindler T; James ER; Abebe Y; Lemiale L; Stabler TC; Murshedkar T; Chen MC; Schwabe C; Ratsirarson J; Rivas MR; Ayekaba MO; Milang DVN; Falla CC; Phiri WP; García GA; Maas CD; Nlavo BM; Tanner M; Billingsley PF; Kim Lee Sim B; Daubenberger C; Hoffman SL; Abdulla S; Richie TL
Am J Trop Med Hyg; 2022 Apr; 106(4):1215-1226. PubMed ID: 35130487
[TBL] [Abstract][Full Text] [Related]
46. A phase IIa, randomized, double-blind, safety, immunogenicity and efficacy trial of Plasmodium falciparum vaccine antigens merozoite surface protein 1 and RTS,S formulated with AS02 adjuvant in healthy, malaria-naïve adults.
Cummings JF; Polhemus ME; Kester KE; Ockenhouse CF; Gasser RA; Coyne P; Wortmann G; Nielsen RK; Schaecher K; Holland CA; Krzych U; Tornieporth N; Soisson LA; Angov E; Heppner DG;
Vaccine; 2024 Apr; 42(12):3066-3074. PubMed ID: 38584058
[TBL] [Abstract][Full Text] [Related]
47. DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection.
Sulyok M; Rückle T; Roth A; Mürbeth RE; Chalon S; Kerr N; Samec SS; Gobeau N; Calle CL; Ibáñez J; Sulyok Z; Held J; Gebru T; Granados P; Brückner S; Nguetse C; Mengue J; Lalremruata A; Sim BKL; Hoffman SL; Möhrle JJ; Kremsner PG; Mordmüller B
Lancet Infect Dis; 2017 Jun; 17(6):636-644. PubMed ID: 28363637
[TBL] [Abstract][Full Text] [Related]
48. Expansion of Functional Myeloid-Derived Suppressor Cells in Controlled Human Malaria Infection.
Lamsfus Calle C; Fendel R; Singh A; Richie TL; Hoffman SL; Kremsner PG; Mordmüller B
Front Immunol; 2021; 12():625712. PubMed ID: 33815377
[TBL] [Abstract][Full Text] [Related]
49. Exploring immunological mechanisms of the whole sporozoite vaccination against P. falciparum malaria.
Mo AX; Pesce J; Hall BF
Vaccine; 2015 Jun; 33(25):2851-7. PubMed ID: 25917675
[TBL] [Abstract][Full Text] [Related]
50. Quantification of Plasmodium knowlesi versus Plasmodium falciparum in the rhesus liver: implications for malaria vaccine studies in rhesus models.
Shears MJ; Seilie AM; Kim Lee Sim B; Hoffman SL; Murphy SC
Malar J; 2020 Aug; 19(1):313. PubMed ID: 32867784
[TBL] [Abstract][Full Text] [Related]
51. Immune responses associated with protection induced by chemoattenuated PfSPZ vaccine in malaria-naive Europeans.
Mouwenda YD; Jochems SP; Van Unen V; Betouke Ongwe ME; de Steenhuijsen Piters WA; Stam KA; Massinga Loembe M; Sim BKL; Esen M; Hoffman SL; Kremsner PG; Fendel R; Mordmüller B; Yazdanbakhsh M
JCI Insight; 2024 May; 9(9):. PubMed ID: 38716733
[TBL] [Abstract][Full Text] [Related]
52. Proteome-wide analysis of a malaria vaccine study reveals personalized humoral immune profiles in Tanzanian adults.
Camponovo F; Campo JJ; Le TQ; Oberai A; Hung C; Pablo JV; Teng AA; Liang X; Sim BKL; Jongo S; Abdulla S; Tanner M; Hoffman SL; Daubenberger C; Penny MA
Elife; 2020 Jul; 9():. PubMed ID: 32662772
[TBL] [Abstract][Full Text] [Related]
53. A genetically attenuated malaria vaccine candidate based on P. falciparum b9/slarp gene-deficient sporozoites.
van Schaijk BC; Ploemen IH; Annoura T; Vos MW; Foquet L; van Gemert GJ; Chevalley-Maurel S; van de Vegte-Bolmer M; Sajid M; Franetich JF; Lorthiois A; Leroux-Roels G; Meuleman P; Hermsen CC; Mazier D; Hoffman SL; Janse CJ; Khan SM; Sauerwein RW
Elife; 2014 Nov; 3():. PubMed ID: 25407681
[TBL] [Abstract][Full Text] [Related]
54. Vaccination with chemically attenuated Plasmodium falciparum asexual blood-stage parasites induces parasite-specific cellular immune responses in malaria-naïve volunteers: a pilot study.
Stanisic DI; Fink J; Mayer J; Coghill S; Gore L; Liu XQ; El-Deeb I; Rodriguez IB; Powell J; Willemsen NM; De SL; Ho MF; Hoffman SL; Gerrard J; Good MF
BMC Med; 2018 Oct; 16(1):184. PubMed ID: 30293531
[TBL] [Abstract][Full Text] [Related]
55. Complete attenuation of genetically engineered Plasmodium falciparum sporozoites in human subjects.
Kublin JG; Mikolajczak SA; Sack BK; Fishbaugher ME; Seilie A; Shelton L; VonGoedert T; Firat M; Magee S; Fritzen E; Betz W; Kain HS; Dankwa DA; Steel RW; Vaughan AM; Noah Sather D; Murphy SC; Kappe SH
Sci Transl Med; 2017 Jan; 9(371):. PubMed ID: 28053159
[TBL] [Abstract][Full Text] [Related]
56. Live attenuated malaria vaccine designed to protect through hepatic CD8⁺ T cell immunity.
Epstein JE; Tewari K; Lyke KE; Sim BK; Billingsley PF; Laurens MB; Gunasekera A; Chakravarty S; James ER; Sedegah M; Richman A; Velmurugan S; Reyes S; Li M; Tucker K; Ahumada A; Ruben AJ; Li T; Stafford R; Eappen AG; Tamminga C; Bennett JW; Ockenhouse CF; Murphy JR; Komisar J; Thomas N; Loyevsky M; Birkett A; Plowe CV; Loucq C; Edelman R; Richie TL; Seder RA; Hoffman SL
Science; 2011 Oct; 334(6055):475-80. PubMed ID: 21903775
[TBL] [Abstract][Full Text] [Related]
57. Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites.
Roestenberg M; Bijker EM; Sim BKL; Billingsley PF; James ER; Bastiaens GJH; Teirlinck AC; Scholzen A; Teelen K; Arens T; van der Ven AJAM; Gunasekera A; Chakravarty S; Velmurugan S; Hermsen CC; Sauerwein RW; Hoffman SL
Am J Trop Med Hyg; 2013 Jan; 88(1):5-13. PubMed ID: 23149582
[TBL] [Abstract][Full Text] [Related]
58. Optimizing Intradermal Administration of Cryopreserved Plasmodium falciparum Sporozoites in Controlled Human Malaria Infection.
Lyke KE; Laurens MB; Strauss K; Adams M; Billingsley PF; James E; Manoj A; Chakravarty S; Plowe CV; Li ML; Ruben A; Edelman R; Green M; Dube TJ; Sim BKL; Hoffman SL
Am J Trop Med Hyg; 2015 Dec; 93(6):1274-1284. PubMed ID: 26416102
[TBL] [Abstract][Full Text] [Related]
59. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria.
Hoffman SL; Billingsley PF; James E; Richman A; Loyevsky M; Li T; Chakravarty S; Gunasekera A; Chattopadhyay R; Li M; Stafford R; Ahumada A; Epstein JE; Sedegah M; Reyes S; Richie TL; Lyke KE; Edelman R; Laurens MB; Plowe CV; Sim BK
Hum Vaccin; 2010 Jan; 6(1):97-106. PubMed ID: 19946222
[TBL] [Abstract][Full Text] [Related]
60. Efficient infection of non-human primates with purified, cryopreserved Plasmodium knowlesi sporozoites.
Chakravarty S; Shears MJ; James ER; Rai U; Kc N; Conteh S; Lambert LE; Duffy PE; Murphy SC; Hoffman SL
Malar J; 2022 Aug; 21(1):247. PubMed ID: 36030292
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
